Jim Gabriele named president and CEO of M2GEN

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Jim Gabriele was named president and chief executive officer of M2GEN.

Gabriele is a data scientist who was most recently senior vice president and chief strategy & data science officer within the Medical Devices Sector at Johnson & Johnson.

M2GEN has linked clinical and genomic databases and runs one of the largest observational research studies in cancer, which tracks patients throughout their lifetime, links longitudinal clinical data with molecular information, and enables a deeper understanding of a patient’s disease.

As senior vice president and chief strategy & data Science officer at Johnson & Johnson, he led global strategy development, pricing strategy, data science, data strategy, digital customer experience and business insights. 

Prior to that, he held senior strategy and data science roles in the Johnson & Johnson Pharmaceutical organization. 

Gabriele succeeds Helge Bastian.

Table of Contents

YOU MAY BE INTERESTED IN

Recently, HHS Secretary Robert F. Kennedy Jr. posted a video montage featuring himself shirtless in jeans, working out with Kid Rock. The duo is in a blue-lit grotto with a cold plunge and sauna. Set to Kid Rock’s “Bawitdaba” and intercut with a selection of patriotic imagery, the video ends with the two men in a hot tub, chugging what appears to be milk.
In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login